Estimating Changes in Medicare Part D and Commercial Insurer Insulin Spending Amid Planned State-Led Biosimilar Insulin Production in California

JAMA Intern Med. 2023 Jul 1;183(7):734-735. doi: 10.1001/jamainternmed.2023.0373.

Authors

Kelly E Anderson¹, Andrew Xuan², Gerard F Anderson², Mariana P Socal²

Affiliations

¹ Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora.
² Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

No abstract available

Plain language summary

This cross-sectional study evaluates the cost savings of state-led manufacturing and selling of biosimilar insulin.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Biosimilar Pharmaceuticals*
California
Health Expenditures
Humans
Insulin / therapeutic use
Insurance Carriers
Medicare Part D*
United States

Substances

Insulin
Biosimilar Pharmaceuticals